摘要
目的 评估埃索美拉唑和奥美拉唑治疗胃溃疡的临床效果及安全性。方法 92例胃溃疡患者,使用硬币法分为对照组与研究组,每组46例。对照组接受奥美拉唑治疗,研究组接受埃索美拉唑治疗。比较两组患者的不良反应发生率,症状消失时间(包括溃疡面愈合时间、胃痛消失时间、炎症消失时间),治疗前后的炎症指标[白细胞介素-8(IL-8)、肿瘤坏死因子-α(TNF-α)]及胃肠激素(胃动素、胃泌素、胆囊收缩素)水平。结果 研究组不良反应发生率4.35%低于对照组的23.91%,差异具有统计学意义(P<0.05)。研究组溃疡面愈合时间(8.54±2.50)d、胃痛消失时间(6.41±0.43)d、炎症消失时间(7.42±1.37)d短于对照组的(12.44±3.52)、(9.66±2.05)、(8.21±0.53)d,差异具有统计学意义(P<0.05)。治疗后,研究组的IL-8(1.45±0.33)ng/L、TNF-α(3.08±0.46)ng/L低于对照组的(2.27±0.52)、(4.27±0.55)ng/L,差异具有统计学意义(P<0.05)。治疗后,研究组的胃动素水平高于对照组,胃泌素、胆囊收缩素水平低于对照组,差异具有统计学意义(P<0.05)。结论 埃索美拉唑在胃溃疡的治疗中效果突出,值得推广。
Objective To evaluate the clinical effect and safety of esomeprazole and omeprazole in the treatment of gastric ulcer.Methods A total of 92 patients with gastric ulcer were divided into the control group and the research group by coin tossing method,with 46 cases in each group.The control group was treated with omeprazole,and the research group was treated with esomeprazole.Both groups were compared in term of incidence of adverse reactions,disappearance time of symptoms(ulcer healing time,disappearance time of gastric pain,and disappearance time of inflammation),inflammation indicators[interleukin-8(IL-8),tumor necrosis factor-α(TNF-α)]and gastrointestinal hormones(motilin,gastrin,cholecystokinin)before and after treatment.Results The incidence of adverse reactions 4.35%in the research group was lower than 23.91%in the control group,and the difference was statistically significant(P<0.05).The ulcer healing time(8.54±2.50)d,disappearance time of stomach pain(6.41±0.43)d,and disappearance time of inflammation(7.42±1.37)d of the research group were shorter than(12.44±3.52),(9.66±2.05)and(8.21±0.53)d of the control group,and the difference was statistically significant(P<0.05).After treatment,the IL-8(1.45±0.33)ng/L and TNF-α(3.08±0.46)ng/L of the research group were lower than(2.27±0.52)and(4.27±0.55)ng/L of the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of motilin in the research group were higher than those in the control group,and the levels of gastrin and cholecystokinin were lower than those in the control group.All the differences were statistically significant(P<0.05).Conclusion Esomeprazole has an outstanding effect in the treatment of gastric ulcer and is worthy of promotion.
作者
翟卓宾
ZHAI Zhuo-bin(Linghai National Health Insurance Center,Jinzhou 121200,China)
出处
《中国现代药物应用》
2021年第22期19-21,共3页
Chinese Journal of Modern Drug Application